Business
Quanterix to Participate in Upcoming Investor Conferences
BILLERICA, Mass., February 26, 2026--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March:
About this update from Quanterix Corporation
[{"type":"text","content":"BILLERICA, Mass., February 26, 2026--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March:","length":312,"tagName":"p"},{"type":"text","content":"46th Annual TD Cowen Healthcare ConferenceFormat: Fireside chat and one-on-one meetingsDate: Wednesday, March 4, 2026Time: 11:50 am ETWebcast: Click here","length":157,"tagName":"p"},{"type":"text","content":"Leerink Global Healthcare Conference 2026Format: Fireside chat and one-on-one meetingsDate: Monday, March 9, 2026Time: 1:00 pm ETWebcast: Click here","length":152,"tagName":"p"},{"type":"text","content":"Interested parties may access a live and recorded webcast of the fireside chats on the Investors section of the company’s website at www.quanterix.com.","length":151,"tagName":"p"},{"type":"text","content":"About Quanterix","length":15,"tagName":"p"},{"type":"text","content":"Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.","length":888,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20260226120026/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"[email protected]","length":25,"tagName":"p"},{"type":"text","content":"Investor RelationsJoshua [email protected]","length":48,"tagName":"p"}]